Candriam S.C.A. Has $26.32 Million Stake in Celcuity, Inc. $CELC

Candriam S.C.A. lowered its position in Celcuity, Inc. (NASDAQ:CELC) by 51.6% in the first quarter, HoldingsChannel.com reports. The fund owned 230,603 shares of the company’s stock after selling 245,767 shares during the quarter. Candriam S.C.A.’s holdings in Celcuity were worth $26,321,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Tudor Investment Corp ET AL bought a new position in Celcuity in the 3rd quarter valued at $1,351,000. Jennison Associates LLC bought a new stake in shares of Celcuity during the fourth quarter worth $22,911,000. HighVista Strategies LLC acquired a new stake in shares of Celcuity in the third quarter valued at $676,000. Geode Capital Management LLC raised its holdings in shares of Celcuity by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after buying an additional 64,213 shares during the last quarter. Finally, Granahan Investment Management LLC acquired a new position in Celcuity during the 3rd quarter worth about $2,434,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Trading Down 5.2%

NASDAQ CELC traded down $5.93 on Friday, reaching $107.58. The company had a trading volume of 698,662 shares, compared to its average volume of 1,142,894. Celcuity, Inc. has a 52 week low of $13.35 and a 52 week high of $151.02. The stock’s 50 day moving average is $111.80 and its 200-day moving average is $110.99. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market cap of $5.25 billion, a price-to-earnings ratio of -27.58 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. Equities analysts predict that Celcuity, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CELC. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research note on Thursday, May 28th. Stifel Nicolaus set a $150.00 price objective on Celcuity in a report on Monday, May 4th. Guggenheim restated a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. HC Wainwright lowered their price target on shares of Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Craig Hallum dropped their price target on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $152.09.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by company insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.